Login to MyKarger

New to MyKarger? Click here to sign up.

Login with Facebook

Forgot your password?

Authors, Editors, Reviewers

For Manuscript Submission, Check or Review Login please go to Submission Websites List.

Submission Websites List

Institutional Login
(Shibboleth or Open Athens)

For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.

Research Article

Free Access

Toll-Like Receptor 2-Independent and MyD88-Dependent Gene Expression in the Mouse Brain

Naert G. · Laflamme N. · Rivest S.

Author affiliations

Laboratory of Molecular Endocrinology, CHUL Research Center and Department of Anatomy and Physiology, Laval University, Québec, Qué., Canada

Corresponding Author

Dr. Serge Rivest

Laboratory of Molecular Endocrinology, CHUL Research Center and

Department of Anatomy and Physiology, Laval University

2705 Laurier boul., Québec, Qué. G1V 4G2 (Canada)

Tel. +1 418 654 2296, Fax +1 418 654 2761, E-Mail Serge.Rivest@crchul.ulaval.ca

Related Articles for ""

J Innate Immun 2009;1:480–493

Do you have an account?

Login Information

Contact Information

I have read the Karger Terms and Conditions and agree.


Toll-like receptors (TLRs) are essential to mount a rapid innate immune reaction to pathogens. Although TLR2 is the key receptor for pathogen-associated molecular patterns from Gram-positive bacteria, a robust transcriptional activation of the gene encoding this receptor takes place in the brain of mice exposed to the TLR4 ligand lipopolysaccharide (LPS). TLR2 gene expression is actually used as a reliable marker of activated microglia in vivo, but its functions remain unknown. The present study investigated the role of this receptor in mediating LPS-induced gene expression in the mouse brain. Immune genes were measured using both in situ hybridization and real time RT-PCR. Despite the robust microglial TLR2 expression, this receptor does not modulate transcriptional activity by TLR4 signaling. TLR2-deficient mice and their wild-type littermates had similar IκBα mRNA levels and induction of innate immune genes from 6 h to 10 days after LPS injection. In contrast, NF-κB activity, cytokine, chemokine, TLR2 and CD14 transcripts were no longer detected in MyD88-deficient mice. Indeed, the hybridization signal for most of the transcripts measured in this study was similar in the brain of MyD88–/– mice exposed to either saline or LPS. These data indicate that while TLR2 transcription is dependent on MyD88 signaling in microglia, this innate immune receptor is not involved in the immune response to LPS. On the other hand, MyD88 pathway is essential for the endotoxin to induce expression of immune genes in the central nervous system.

© 2009 S. Karger AG, Basel


  1. Akira S, Uematsu S, Takeuchi, O: Pathogen recognition and innate immunity. Cell 2006;124:783–801.
  2. Glezer I, Simard AR, Rivest S: Neuroprotective role of the innate immune system by microglia. Neuroscience 2007;147:867–883.
  3. Turrin NP, Rivest S: Molecular and cellular immune mediators of neuroprotection. Mol Neurobiol 2006;34:221–242.
  4. Aloisi F: Immune function of microglia. Glia 2001;36:165–179.
  5. Olson JK, Miller SD: Microglia initiate central nervous system innate and adaptive immune responses through multiple TLRs. J Immunol 2004;173:3916–3924.
  6. Uematsu S, Akira S: Toll-like receptors and innate immunity. J Mol Med 2006;84:712–725.
  7. Uematsu S, Akira S: Toll-like receptors and type I interferons. J Biol Chem 2007;282:15319–15323.
  8. Adachi O, Kawai T, Takeda K, Matsumoto M, Tsutsui H, Sakagami M, Nakanishi K, Akira S: Targeted disruption of the MyD88 gene results in loss of IL-1- and IL-18-mediated function. Immunity 1998;9:143–150.
  9. Kopp E, Medzhitov R: Recognition of microbial infection by Toll-like receptors. Curr Opin Immunol 2003;15:396–401.
  10. Takeda K, Akira S: TLR signaling pathways. Semin Immunol 2004;16:3–9.
  11. Takeda K, Akira S: Toll-like receptors in innate immunity. Int Immunol 2005;17:1–14.
  12. Takeda K, Kaisho T, Akira S: Toll-like receptors. Annu Rev Immunol 2003;21:335–376.
  13. Medzhitov R, Preston-Hurlburt P, Janeway CA Jr: A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature 1997;388:394–397.
  14. Poltorak A, He X, Smirnova I, Liu MY, Van Huffel C, Du X, Birdwell D, Alejos E, Silva M, Galanos C, Freudenberg M, Ricciardi-Castagnoli P, Layton B, Beutler B: Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science 1998;282:2085–2088.
  15. Wright SD: Toll, a new piece in the puzzle of innate immunity. J Exp Med 1999;189:605–609.
  16. Kawasaki K, Akashi S, Shimazu R, Yoshida T, Miyake K, Nishijima M: Involvement of TLR4/MD-2 complex in species-specific lipopolysaccharide-mimetic signal transduction by Taxol. J Endotoxin Res 2001;7:232–236.
  17. Shimazu R, Akashi S, Ogata H, Nagai Y, Fukudome K, Miyake K, Kimoto M: MD-2, a molecule that confers lipopolysaccharide responsiveness on Toll-like receptor 4. J Exp Med 1999;189:1777–1782.
  18. Nadeau S, Rivest S: Role of microglial-derived tumor necrosis factor in mediating CD14 transcription and nuclear factor kappa B activity in the brain during endotoxemia. J Neurosci 2000;20:3456–3468.
  19. Nadeau S, Rivest S: Endotoxemia prevents the cerebral inflammatory wave induced by intraparenchymal lipopolysaccharide injection: role of glucocorticoids and CD14. J Immunol 2002;169:3370–3381.
  20. Nguyen MD, Julien JP, Rivest S: Innate immunity: the missing link in neuroprotection and neurodegeneration? Nature Rev Neurosci 2002;3:216–227.
  21. Glezer I, Lapointe A, Rivest S: Innate immunity triggers oligodendrocyte progenitor reactivity and confines damages to brain injuries. FASEB J 2006;20:750–752.
  22. Laflamme N, Echchannaoui H, Landmann R, Rivest S: Cooperation between toll-like receptor 2 and 4 in the brain of mice challenged with cell wall components derived from Gram-negative and Gram-positive bacteria. Eur J Immunol 2003;33:1127–1138.
  23. Laflamme N, Soucy G, Rivest S: Circulating cell wall components derived from Gram-negative, not Gram-positive, bacteria cause a profound induction of the gene-encoding Toll-like receptor 2 in the CNS. J Neurochem 2001;79:648–657.
  24. Wooten RM, Ma Y, Yoder RA, Brown JP, Weis JH, Zachary JF, Kirschning CJ, Weis JJ: Toll-like receptor 2 is required for innate, but not acquired, host defense to Borrelia burgdorferi. J Immunol 2002;168:348–355.
  25. Simard AR, Rivest S: Neuroprotective effects of resident microglia following acute brain injury. J Comp Neurol 2007;504:716–729.
  26. Paxinos G, Franklin K: The Mouse Brain in Stereotaxic Coordinates, ed 2. San Diego, Academic Press, 2001.
  27. Laflamme N, Lacroix S, Rivest S: An essential role of interleukin-1beta in mediating NF-kappaB activity and COX-2 transcription in cells of the blood-brain barrier in response to a systemic and localized inflammation but not during endotoxemia. J Neurosci 1999;19:10923–10930.
  28. Laflamme N, Rivest S: Toll-like receptor 4: the missing link of the cerebral innate immune response triggered by circulating Gram-negative bacterial cell wall components. FASEB J 2001;15:155–163.
  29. Liu Y, Wang Y, Yamakuchi M, Isowaki S, Nagata E, Kanmura Y, Kitajima I, Maruyama I: Upregulation of toll-like receptor 2 gene expression in macrophage response to peptidoglycan and high concentration of lipopolysaccharide is involved in NF-kappa B activation. Infect Immun 2001;69:2788–2796.
  30. Soucy G, Boivin G, Labrie F, Rivest S: Estradiol is required for a proper immune response to bacterial and viral pathogens in the female brain. J Immunol 2005;174:6391–6398.
  31. Blais V, Rivest S: Effects of TNF-alpha and IFN-gamma on nitric oxide-induced neurotoxicity in the mouse brain. J Immunol 2004;172:7043–7052.
  32. Musikacharoen T, Matsuguchi T, Kikuchi T, Yoshikai Y: NF-kappa B and STAT5 play important roles in the regulation of mouse Toll-like receptor 2 gene expression. J Immunol 2001;166:4516–4524.
  33. Faure E, Thomas L, Xu H, Medvedev A, Equils O, Arditi M: Bacterial lipopolysaccharide and IFN-gamma induce Toll-like receptor 2 and Toll-like receptor 4 expression in human endothelial cells: role of NF-kappa B activation. J Immunol 2001;166:2018–2024.
  34. Wang T, Lafuse WP, Zwilling BS: Regulation of Toll-like receptor 2 expression by macrophages following Mycobacterium avium infection. J Immunol 2000;165:6308–6313.
  35. Babcock AA, Wirenfeldt M, Holm T, Nielsen HH, Dissing-Olesen L, Toft-Hansen H, Millward JM, Landmann R, Rivest S, Finsen B, Owens T: Toll-like receptor 2 signaling in response to brain injury: an innate bridge to neuroinflammation. J Neurosci 2006;26:12826–12837.
  36. Boivin A, Pineau I, Barrette B, Filali M, Vallieres N, Rivest S, Lacroix S: Toll-like receptor signaling is critical for Wallerian degeneration and functional recovery after peripheral nerve injury. J Neurosci 2007;27:12396–12406.
  37. Kigerl KA, Lai W, Rivest S, Hart RP, Satoskar AR, Popovich PG: Toll-like receptor (TLR)-2 and TLR-4 regulate inflammation, gliosis, and myelin sparing after spinal cord injury. J Neurochem 2007;102:37–50.
  38. O’Neill LA, Bowie AG: The family of five: TIR-domain-containing adaptors in Toll-like receptor signalling. Nat Rev Immunol 2007;7:353–364.
  39. Kaisho T, Akira S: Toll-like receptor function and signaling. J Allergy Clin Immunol 2006;117:979–987; quiz 988.
  40. Kawai T, Adachi O, Ogawa T, Takeda K, Akira S: Unresponsiveness of MyD88-deficient mice to endotoxin. Immunity 1999;11:115–122.
  41. Kawai T, Takeuchi O, Fujita T, Inoue J, Muhlradt PF, Sato S, Hoshino K, Akira S: Lipopolysaccharide stimulates the MyD88-independent pathway and results in activation of IFN-regulatory factor 3 and the expression of a subset of lipopolysaccharide-inducible genes. J Immunol 2001;167:5887–5894.

Article / Publication Details

First-Page Preview
Abstract of Research Article

Received: September 09, 2008
Accepted: April 17, 2009
Published online: June 20, 2009
Issue release date: August 2009

Number of Print Pages: 14
Number of Figures: 6
Number of Tables: 3

ISSN: 1662-811X (Print)
eISSN: 1662-8128 (Online)

For additional information: https://www.karger.com/JIN

Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.